Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMJKWMA)

Drug Name
Tanezumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Cancer related pain MG30 Phase 3 [1]
Chronic low back pain MG30.02 Phase 3 [2]
Neuropathic pain 8E43.0 Phase 3 [2]
Osteoarthritis FA00-FA05 Phase 3 [2]
Pain MG30-MG3Z Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMJKWMA

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nerve growth factor (NGF) TTDN3LF NGF_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Nerve growth factor (NGF) DTT NGF 3.307 3 3.621 2.511
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Cancer related pain
ICD Disease Classification MG30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Nerve growth factor (NGF) DTT NGF 5.57E-02 -0.06 -0.31
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8415).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)